Request for Interest (RFI)
BIO Ventures for Global Health (BVGH) invites investigators to submit information regarding their interests in conducting cancer clinical trials (feasibility studies) in sub-Saharan Africa (herein referred to as “Africa”). The studies described must (1) be conducted in Africa by an Africa-based investigator or with an Africa-based partner, (2) focus on one or more of the most common cancers in African populations, and (3) be aimed at improving African cancer patients’ health outcomes.

Responses to this RFI may be shared, wholly or in part, with potential funders of BVGH's clinical trial study pool (AC3T Study Pool). Please do not include any confidential or proprietary information in your submission.

Please complete and submit one form for each cancer feasibility study you are interested in performing in Africa.

For more information about BVGH and the AC3T Study Pool, please email Katy Graef (kgraef@bvgh.org).


Sign in to Google to save your progress. Learn more
Section 1: Respondent Information
Respondent Last (Family) Name *
Respondent First (Given) Name (s) *
Respondent Title(s) (e.g., Professor of Medicine) *
Respondent Email Address *
Respondent Phone Number (with country code)
Respondent Organization Name *
Address *
City *
Province, State, or Territory (if applicable)
Postal Code (if applicable)
Country *
Relevant Prior Experience Conducting Cancer Clinical Trials *
(1500 characters maximum)
Section 2: Cancer Clinical Trial Information
Clinical trials are defined as clinical research that evaluates and tests therapies, medications, and/or devices. Cancer feasibility studies are defined as investigator-initiated clinical trials using current standards of care (FDA approved drugs), a primary goal of which is to demonstrate that a site can conduct a cancer clinical trial. Social, behavioral, and early-stage genomic studies are not consistent with the intent of this RFI.

Study Title *
Cancer Indication(s) *
Check all that apply. Please note that for the purposes of this RFI, studies focused on high-prevalence cancers are strongly preferred.
Required
Other
Estimated Study Budget *
Inclusive of direct and indirect costs, in US dollars
Does the Study Budget Include Funding to Procure the Study Medication(s) or Intervention(s)? *
If "No," How Will the Study Intervention(s) be Obtained/Paid For?
(1500 characters maximum)
What Percentage of the Study Budget Would You Anticipate Requesting from the AC3T Study Pool? *
(0-100%)
If the percentage is greater than 0 but less than 100, list other anticipated funding sources and the estimated percent contribution of each to the total study budget
(1500 characters maximum)
Estimated Study Duration *
(In months)
Study Background *
(1500 characters maximum)
Study Objectives *
(1500 characters maximum)
How is the Study Anticipated to Improve Cancer Patient Outcomes in Africa? *
(1500 characters maximum)
Study Design *
(including arms and interventions, data acquisition and analysis methods, endpoint measurements, and planned correlatives as relevant) (1500 characters max)
Do You Plan to Bank Study Specimens for Future Investigations? *
If "Yes," Please Describe Relevant Experience Managing Biobanks
(1500 characters maximum)
Study Location(s) (country name[s]) *
Study Location(s) (additional details, as available [e.g., hospitals, cities])
(1500 characters maximum)
Study Population(s) (check all that apply) *
Required
Other Co-Morbidity
Study Eligibility Criteria *
(1500 characters maximum)
Anticipated Number of Patients (total across all study arms) *
Key Partners (individuals and/or organizations, as applicable)
(1500 characters maximum)
Primary Outcome Measures *
(1500 characters maximum)
Secondary Outcome Measures (if applicable)
(1500 characters maximum)
Expected Next Steps if Study is Successful *
(1500 characters maximum)
Submit
Clear form
Never submit passwords through Google Forms.
This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Privacy Policy
Google Forms